Sino Biopharmaceutical Limited (FRA:SMZ1)

Market Cap	7.93B
Revenue (ttm)	3.82B
Net Income (ttm)	463.14M
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	17.12
Forward PE	19.20
Dividend	0.01 (1.61%)
Ex-Dividend Date	Jun 16, 2025

Volume	n/a
Average Volume	31,083
Open	0.4425
Previous Close	0.4375
Day's Range	0.4364 - 0.4425
52-Week Range	0.3001 - 0.4799
Beta	n/a
RSI	54.41
Earnings Date	May 16, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. It offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under An...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 24,379
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SMZ1

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY